Discover open access scientific publications

Search, annotate, share and cite publications

Publications by L. Eldjerou

Correlative Analyses of Cytokine Release Syndrome and Neurological Events in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Related publications

Cytokine Release Syndrome and Neurotoxicity by Baseline Tumor Burden in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Intravenous Immunoglobulin Therapy Use in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated With Tisagenlecleucel in the Juliet Trial

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hematological Oncology
MedicineCancer ResearchOncologyHematology
2019English

Pcn72 - Budget Impact Analysis of Tisagenlecleucel for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in England

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Long-Term Follow-Up of Tisagenlecleucel in Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Updated Analysis of Juliet Study

Biology of Blood and Marrow Transplantation
TransplantationHematology
2019English

Pcn177 - Cost-Effectiveness of Tisagenlecleucel for Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma : A Canadian Societal Perspective

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Bendamustine Combined With Rituximab for Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

Annals of Hematology
MedicineHematology
2013English

Emerging Therapies for the Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma

Current Oncology
Oncology
2019English

Bone Marrow Molecular Markers Associated With Relapsed/Refractory Activated B-Cell-Like Diffuse Large B-Cell Lymphoma

BioMed Research International
ImmunologyMolecular BiologyBiochemistryMicrobiology MedicineGenetics
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy